https://www.selleckchem.com/products/cay10444.html
3 vs. 0.48 (P=0.033); CD8+CD38+HLA-DR+, -1.6 vs. 1.3 (P=0.02)] and senescent [CD4+CD28-CD57+, -0.3 vs. 0.26 (P=0.04); CD8+CD28-CD57+, -6.1 vs. 3.8 (P=0.002)] T lymphocytes. In addition, the median CD4/CD8 ratio increased by 0.35 in patients in the raltegravir group vs. 0.03 in the other arms (P=0.002). Differences between groups in monocyte subpopulations or soluble inflammation markers were not observed. Losartan had no effect on lymphoid fibrosis or immune activation/inflammation. Conversely, switching to a regimen with raltegravir s
Like
Comment
Share
